Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Could Beta-Blocker Use in Pregnant Women Cause Fetal Heart Defects?

April 19, 2017 By Law Offices of Thomas J. Lamb, P.A.


On April 3, 2017, updated results from the National Birth Defects Prevention Study (NBDPS) were released and published in the article “Maternal Antihypertensive Medication Use and Congenital Heart Defects” (Abstract only).

This study found that there was a statistically significant association between β-blocker use in pregnant women and fetal congenital heart defects.

The most commonly used β-blockers in the study were Trandate (labetalol), Tenormin (atenolol), Hemangeol / Inderal / Innopran (propranolol), and Lopressor / Toprol (metoprolol).

The researcher’s findings and specific odds ratios pertaining to an increased risk of congenital heart defects are described in the excerpt from the Abstract, below:

We observed increased risk of 4 CHD phenotypes, regardless of antihypertensive medication class reported: coarctation of the aorta (2.50 [1.52–4.11]), pulmonary valve stenosis (2.19 [1.44–3.34]), perimembranous ventricular septal defect (1.90 [1.09–3.31]), and secundum atrial septal defect (1.94 [1.36–2.79]).

Furthermore, researchers stated, “We calculated adjusted odds ratios [95% confidence intervals] to estimate the risk of specific CHDs associated with antihypertensive use during the month before conception through the third month of pregnancy, controlling for maternal age, race/ethnicity, body mass index, first trimester cigarette smoking, and NBDPS site” (emphasis added).

However, a recent JAMA Research Letter casts doubt on the sufficiency of these controls, claiming that statistic significance no longer exists “after adjusting for maternal age, maternal body mass index, and maternal comorbidities” (emphasis added).

While the authors of the letter acknowledge that “maternal β-blocker exposure was associated with significantly increased odds of fetal congenital cardiac anomalies,” they attribute the association to possible confounding, stating “β-blocker exposure was not associated with increased risks of fetal congenital cardiac anomalies after adjustment for maternal comorbidities.”

Of note, the research letter does point out that “these findings do not definitively rule out the possibility of fetal congenital defects in association with β-blocker use.”  More expansive research is needed before it can be definitively determined whether β-blockers are associated with fetal congenital heart defects when used by pregnant mothers.

We will continue to monitor the medical literature concerning the association with β-blockers and fetal congenital heart defects.  Updated information will be added to this post as it becomes available.

 

Written by: Heather Helmendach, Legal Assistant
Law Offices of Thomas J. Lamb, P.A.

 

Drug Injury Watch: Side Effects News & Reports

Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: american heart association, antihypertensive drugs, atenolol, beta-blockers, cardiovascular malformations, coarctation of the aorta, congenital heart defects, drug side effects, fetal heart problems, Hemangeol, hypertension, hypertension drugs, Inderal, Innopran, JAMA, Lopressor, metoprolol, National Birth Defects Prevention Study, perimembranous ventricular septal defect, propranolol, pulmonary valve stenosis, randate (labetalol), secundum atrial septal defect, side effects, Tenormin, Toprol

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.